215 related articles for article (PubMed ID: 25244877)
1. Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans.
Valentín II; Rivera G; Nieves-Plaza M; Cruz I; Renta JY; Cadilla CL; Feliu JF; Seip RL; Ruaño G; Duconge J
P R Health Sci J; 2014 Sep; 33(3):97-104. PubMed ID: 25244877
[TBL] [Abstract][Full Text] [Related]
2. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.
Valentin II; Vazquez J; Rivera-Miranda G; Seip RL; Velez M; Kocherla M; Bogaard K; Cruz-Gonzalez I; Cadilla CL; Renta JY; Feliu JF; Ramos AS; Alejandro-Cowan Y; Gorowski K; Ruaño G; Duconge J
Ann Pharmacother; 2012 Feb; 46(2):208-18. PubMed ID: 22274142
[TBL] [Abstract][Full Text] [Related]
3. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.
Duconge J; Cadilla CL; Windemuth A; Kocherla M; Gorowski K; Seip RL; Bogaard K; Renta JY; Piovanetti P; D'Agostino D; Santiago-Borrero PJ; Ruaño G
Ethn Dis; 2009; 19(4):390-5. PubMed ID: 20073138
[TBL] [Abstract][Full Text] [Related]
5. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
[TBL] [Abstract][Full Text] [Related]
6. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.
Ma C; Zhang Y; Xu Q; Yang J; Zhang Y; Gao L; Xu B; Wang H; Li Y; Lu C; Yin T
Int J Hematol; 2012 Dec; 96(6):719-28. PubMed ID: 23104259
[TBL] [Abstract][Full Text] [Related]
7. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies.
Villagra D; Duconge J; Windemuth A; Cadilla CL; Kocherla M; Gorowski K; Bogaard K; Renta JY; Cruz IA; Mirabal S; Seip RL; Ruaño G
Clin Chim Acta; 2010 Sep; 411(17-18):1306-11. PubMed ID: 20488169
[TBL] [Abstract][Full Text] [Related]
8. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
9. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
An SH; Lee KE; Chang BC; Gwak HS
J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
[TBL] [Abstract][Full Text] [Related]
10. VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy.
Mandic D; Bozina N; Mandic S; Samardzija M; Milostic-Srb A; Rumora L
Int J Clin Pharmacol Ther; 2015 Nov; 53(11):905-13. PubMed ID: 26445138
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.
Gaikwad T; Ghosh K; Kulkarni B; Kulkarni V; Ross C; Shetty S
Eur J Pharmacol; 2013 Jun; 710(1-3):80-4. PubMed ID: 23602689
[TBL] [Abstract][Full Text] [Related]
12. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
[TBL] [Abstract][Full Text] [Related]
13. Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients.
Zhang S; Zhao M; Zhong S; Niu J; Zhou L; Zhu B; Su H; Cao W; Xing Q; Yan H; Han X; Fu Q; Li Q; Chen L; Yang F; Zhang N; Wu H; He L; Qin S
Pharmacogenet Genomics; 2024 Jun; 34(4):105-116. PubMed ID: 38470454
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
[TBL] [Abstract][Full Text] [Related]
15. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.
Yang J; Chen Y; Li X; Wei X; Chen X; Zhang L; Zhang Y; Xu Q; Wang H; Li Y; Lu C; Chen W; Zeng C; Yin T
Int J Cardiol; 2013 Oct; 168(4):4234-43. PubMed ID: 23932037
[TBL] [Abstract][Full Text] [Related]
17. Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients.
Ramos AS; Seip RL; Rivera-Miranda G; Felici-Giovanini ME; Garcia-Berdecia R; Alejandro-Cowan Y; Kocherla M; Cruz I; Feliu JF; Cadilla CL; Renta JY; Gorowski K; Vergara C; Ruaño G; Duconge J
Pharmacogenomics; 2012 Dec; 13(16):1937-50. PubMed ID: 23215886
[TBL] [Abstract][Full Text] [Related]
18. Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements.
Zhou L; Ding Y; Gao Y; Yang B; Bao J; Ma J
Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):1-9. PubMed ID: 31914334
[No Abstract] [Full Text] [Related]
19. Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study.
Sridharan K; Modi T; Bendkhale S; Kulkarni D; Gogtay NJ; Thatte UM
Curr Clin Pharmacol; 2016; 11(1):62-8. PubMed ID: 26777610
[TBL] [Abstract][Full Text] [Related]
20. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.
Gage BF; Bass AR; Lin H; Woller SC; Stevens SM; Al-Hammadi N; Li J; Rodríguez T; Miller JP; McMillin GA; Pendleton RC; Jaffer AK; King CR; Whipple BD; Porche-Sorbet R; Napoli L; Merritt K; Thompson AM; Hyun G; Anderson JL; Hollomon W; Barrack RL; Nunley RM; Moskowitz G; Dávila-Román V; Eby CS
JAMA; 2017 Sep; 318(12):1115-1124. PubMed ID: 28973620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
